Phio Pharmaceuticals Corp. Common Stock (PHIO)
Stock · NASDAQ · Health Care
$0.8861as of 10/16/2026
Price chart
Active signals
PHIO Signal Track Record
How signals performed across all stocks →What PHIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 23 | +3.7% | 52% | September 25, 2026 |
| Bollinger Band BreakdownActive now | 22 | +2.0% | 50% | July 15, 2026 |
| Bollinger Band Breakout | 18 | -12.1% | 28% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -2.5% | 50% | September 2, 2026 |
| Any 20-session window (baseline) | -6.8% | 33% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PHIO
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T ce…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6
- Website
- phiopharma.com/
Fundamentals
- 1-day range
- $0.885$0.9425
- Market cap
- $12.31M
- P/E (trailing)
- —
- P/E (forward)
- -1.49
- EPS (trailing)
- $-1.39
- Dividend yield
- —
- Beta
- 0.90
- Avg. volume
- 159.8K
- Dividend pay date
- January 15, 2020
How Phio Pharmaceuticals Corp. Common Stock Makes Money
Where the revenue actually goes — FY2019 annual results
Source: 10-K filed Mar 26, 2020 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Phio Pharmaceuticals Corp. Common Stock Competitors
Chosen by industry and closest market cap.
- PHIOPhio Pharmaceuticals Corp. Common Stock$0.871▼ 5.94%Market cap $12.31MP/E —$0.8127$4.19
- BLRXBioLineRx Ltd. American Depositary Shares$2.01▼ 1.95%Market cap $12.14MP/E Infinity$1.1$2.3
- VTGNVistagen Therapeutics Inc. Common Stock$0.2▼ 4.76%Market cap $12.59MP/E —$0.198$5.14
- CMMBChemomab Therapeutics Ltd. American Depositary Share$1.26▼ 1.94%Market cap $12.95MP/E —$1.05$3.5
- KPRXKiora Pharmaceuticals Inc. Common Stock$2.4▼ 0.41%Market cap $11.35MP/E —$1.76$2.91
- PBMPsyence Biomedical Ltd. Common Shares$4.22▼ 2.31%Market cap $13.31MP/E —$1.92$143.5
- GTBPGT Biopharma Inc. Common Stock$7.03▼ 4.48%Market cap $13.35MP/E —$4.91$34.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PHIO Phio Pharmaceuticals Corp. Common Stock | $12.31M | — | $0.871 | ▼ 5.94% | $0.8127$4.19 |
| BLRX BioLineRx Ltd. American Depositary Shares | $12.14M | Infinity | $2.01 | ▼ 1.95% | $1.1$2.3 |
| VTGN Vistagen Therapeutics Inc. Common Stock | $12.59M | — | $0.2 | ▼ 4.76% | $0.198$5.14 |
| CMMB Chemomab Therapeutics Ltd. American Depositary Share | $12.95M | — | $1.26 | ▼ 1.94% | $1.05$3.5 |
| KPRX Kiora Pharmaceuticals Inc. Common Stock | $11.35M | — | $2.4 | ▼ 0.41% | $1.76$2.91 |
| PBM Psyence Biomedical Ltd. Common Shares | $13.31M | — | $4.22 | ▼ 2.31% | $1.92$143.5 |
| GTBP GT Biopharma Inc. Common Stock | $13.35M | — | $7.03 | ▼ 4.48% | $4.91$34.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026Yahoo · 10/6/2026
- OTC Markets Group Announces Agenda for Third Annual Global Markets Forum, October 7th & 8thYahoo · 10/5/2026
- Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd ConferenceYahoo · 10/5/2026
- Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 ConferenceYahoo · 9/23/2026
- Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell CarcinomaYahoo · 9/14/2026
- Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceYahoo · 9/11/2026
Insider Activity
Insider Actions →- Plott Ronald Todd · September 28, 2026 · Grant17.0K
- Lisa Cabott Carson · September 28, 2026 · Grant108.0K
- Robert J. Bitterman · September 28, 2026 · Grant400.0K
- Patricia A. Bradford · September 24, 2026 · Buy6.5K @ $1.01
- Robert J. Bitterman · September 22, 2026 · Buy2.0K @ $1.03
- Patricia A. Bradford · September 15, 2026 · Buy12.0K @ $1.03
- Robert J. Bitterman · September 11, 2026 · Tax Withholding68.5K @ $1.03
- Lisa Cabott Carson · September 11, 2026 · Tax Withholding12.9K @ $1.03
- Plott Ronald Todd · August 19, 2026 · Buy15.0K @ $1.14
- Robert J. Bitterman · August 18, 2026 · Buy10.0K @ $1.06
Institutional Ownership
March 31, 2026
- Total shares held
- 630.3K
- Total value held
- $702.5K
- Institutional holders
- 23
- Unknown147.3K
- Unknown119.2K
- Unknown79.9K
- Unknown45.0K
- Unknown34.7K
- Unknown32.5K
- Unknown30.0K
- Unknown27.0K
- Unknown24.9K
- Unknown23.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
PHIO to Speak at NIBA Conference as OTC Markets Announces Forum
Phio Pharmaceuticals will present at the National Investment Banking Association’s 153rd conference. The presentation gives the company a chance to share updates with investors. At the same time, OTC Markets Group released the agenda for its third annual Global Markets Forum, an event that could influence activity on the OTC market where PHIO trades.
PHIO to Speak at NIBA Conference as OTC Markets Announces Forum. Phio Pharmaceuticals will present at the National Investment Banking Association’s 153rd conference. The presentation gives the company a chance to share updates with investors. At the same time, OTC Markets Group released the agenda for its third annual Global Markets Forum, an event that could influence activity on the OTC market where PHIO trades.